RBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $130 Price Target

Benzinga Newsdesk www.benzinga.com Negative 93.1%

Neg 93.1% Neu 0% Pos 0%

RBC Capital analyst Shagun Singh reiterates Abbott Laboratories (NYSE:ABT) with a Outperform and maintains $130 price target.